No Opposition. No suit, action, or proceeding shall be pending or threatened on the Closing Date before or by any court or governmental authority seeking to restrain or prohibit the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby.
No Opposition. Prior to the Expiration Date, the Securityholder agrees not to take, or cause to be taken, any action in the Securityholder’s capacity as a holder of Securities of the Company that would, or would be reasonably likely to, have the purpose or effect of preventing the consummation of the Transaction and the transactions contemplated by the Merger Agreement. Prior to the Expiration Date, the Securityholder agrees to take, or cause to be taken in its capacity as a holder of Securities of the Company, all actions necessary to effect the Transaction and the transactions contemplated by the Merger Agreement.
No Opposition. No suit, action or proceeding shall be pending or threatened at any time prior to or on the Closing Date before or by any court or governmental body seeking to restrain or prohibit, or damages or other relief in connection with, the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby or which might materially and adversely affect the business or properties or condition, financial or other, or results of operations of Seller.
No Opposition. No suit, action or proceeding shall be pending or threatened at any time prior to or on the date of the Closing before or by any Governmental Entity seeking to restrain or prohibit, or damages or other relief in connection with, the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby or which might materially and adversely affect the business or properties or condition, financial or other, or results of operations of Parent or Merger Sub.
No Opposition. Shareholder agrees that he or she shall not take, or cause to be taken, any action that (i) is reasonably likely to result in a breach of any representation, warranty, covenant or other obligation of Redwood Empire or NBR under the Plan or that is reasonably likely to preclude fulfillment of a condition precedent under the Plan to Redwood Empire's or NBR's obligation to consummate either of the Mergers or (ii) is intended to, or is reasonably likely to, impede, interfere with, delay, postpone, discourage or adversely affect either of the Mergers or any of the other transactions contemplated by the Plan.
No Opposition. No suit, action or proceeding shall be pending or overtly threatened on the Transfer Date before or by any court or Governmental Entity seeking to restrain or prohibit the consummation of the transactions contemplated by this Agreement.
No Opposition. Prior to the Expiration Date and subject to Section 9.16, the Stockholder agrees not to take, or cause to be taken, any action inconsistent with the consummation of the Company Merger and the transactions contemplated by the Merger Agreement. Prior to the Expiration Date, the Stockholder agrees to take, or cause to be taken, all actions necessary to facilitate, encourage or otherwise support the Company Merger and the transactions contemplated by the Merger Agreement.
No Opposition. The Stockholder agrees not to take, or cause to be taken, any action inconsistent with the consummation of the Merger and the transactions contemplated by the Merger Agreement. The Stockholder agrees to take, or cause to be taken, all actions necessary to facilitate, encourage or otherwise support the Merger and the transactions contemplated by the Merger Agreement. NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, THE COVENANTS AND AGREMENTS CONTAINED IN THIS AGREEMENT SHALL NOT BE DEEMED TO PROHIBIT THE STOCKHOLDER, ACTING AS A DIRECTOR OF OLYMPIC (IF APPLICABLE), FROM EXERCISING HIS FIDUCIARY OBLIGATIONS IN THE EVENT OF A SUPERIOR PROPOSAL WITH RESPECT TO OLYMPIC
No Opposition. No suit, action or proceeding shall be pending or threatened at any time prior to or on the date of the Closing before or by any Governmental Entity seeking to restrain or prohibit, or damages or other relief in connection with, the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby or which might materially and adversely affect the business or properties or condition, financial or other, or results of operations of ECI.
No Opposition. The Roche Entities represent and warrant that they have not filed any opposition in the European Patent Office to Tanox's patent No. EP-B-407392 relating to Anti-IgE Antibodies or taken any other actions to re oppose, request the examination of, or otherwise challenge the validity or enforceability, directly or indirectly, of any Tanox patents covering Anti-IgE Antibodies.